List view / Grid view

TOLREMO Therapeutics

 

article

Looking beyond traditional oncogenic pathways to break cancer resistance

25 September 2024 | By

Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…